QNRX
Quoin Pharmaceuticals, Ltd.Healthcare · $11M market cap
Verdict
We can't put a fair value on QNRX right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow QNRX
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Aug 31, 2026: 8 open-market purchases worth $455K. Why purchases matter
Purchases
Culverwell Anthony James
director · 2026-08-31
Bought
$19K
Culverwell Anthony James
director · 2026-08-31
Bought
$30K
Lawlor Sally Bridget
Chief Financial Officer · 2026-08-31
Bought
$31K
Lawlor Sally Bridget
Chief Financial Officer · 2026-08-31
Bought
$50K
Myers Michael
Chief Executive Officer · 2026-08-31
Bought
$62K
Myers Michael
Chief Executive Officer · 2026-08-31
Bought
$100K
Carter Denise P.
Chief Operating Officer · 2026-08-31
Bought
$62K
Carter Denise P.
Chief Operating Officer · 2026-08-31
Bought
$100K
About Quoin Pharmaceuticals, Ltd.
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works